JP2023133525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023133525A5 JP2023133525A5 JP2023126665A JP2023126665A JP2023133525A5 JP 2023133525 A5 JP2023133525 A5 JP 2023133525A5 JP 2023126665 A JP2023126665 A JP 2023126665A JP 2023126665 A JP2023126665 A JP 2023126665A JP 2023133525 A5 JP2023133525 A5 JP 2023133525A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- cancer
- antibody
- medicament according
- severity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936168P | 2014-02-05 | 2014-02-05 | |
| US61/936,168 | 2014-02-05 | ||
| JP2016550261A JP2017507931A (ja) | 2014-02-05 | 2015-02-05 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2020144077A JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144077A Division JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023133525A JP2023133525A (ja) | 2023-09-22 |
| JP2023133525A5 true JP2023133525A5 (https=) | 2023-12-04 |
| JP7767361B2 JP7767361B2 (ja) | 2025-11-11 |
Family
ID=53778458
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550261A Pending JP2017507931A (ja) | 2014-02-05 | 2015-02-05 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2020144077A Active JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2023126665A Active JP7767361B2 (ja) | 2014-02-05 | 2023-08-03 | がん及び感染症の治療方法並びに治療用組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550261A Pending JP2017507931A (ja) | 2014-02-05 | 2015-02-05 | がん及び感染症の治療方法並びに治療用組成物 |
| JP2020144077A Active JP7328187B2 (ja) | 2014-02-05 | 2020-08-28 | がん及び感染症の治療方法並びに治療用組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11213583B2 (https=) |
| EP (1) | EP3102233B1 (https=) |
| JP (3) | JP2017507931A (https=) |
| CN (1) | CN105979961B (https=) |
| CA (1) | CA2937035A1 (https=) |
| WO (1) | WO2015120198A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2011133636A1 (en) | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| CA2937035A1 (en) * | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| US20170165364A1 (en) * | 2014-02-21 | 2017-06-15 | Idac Theranostics, Inc. | Therapeutic agent for solid cancer |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| JP6715491B2 (ja) * | 2014-06-11 | 2020-07-01 | Ｉｄａｃセラノスティクス株式会社 | 免疫チェックポイント制御剤の副作用低減方法 |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| CA2969417A1 (en) * | 2014-12-05 | 2016-06-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
| US20180296663A1 (en) * | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| CN119564879A (zh) * | 2015-08-18 | 2025-03-07 | 乐天医药生技股份有限公司 | 用于光免疫疗法的组合物、联用及相关方法 |
| AU2016308286B2 (en) | 2015-08-18 | 2022-04-07 | Rakuten Medical, Inc. | Phthalocyanine dye conjugates and their storage |
| PE20240096A1 (es) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador |
| TWI781934B (zh) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
| EP3496707A4 (en) * | 2016-08-09 | 2020-03-25 | Angimmune, LLC | Treatment of cancer using a combination of immunomodulation and check point inhibitors |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| EP3705124A4 (en) * | 2017-10-30 | 2021-07-14 | Ube Industries, Ltd. | PHARMACEUTICAL COMPOSITION ADMINISTERED IN COMBINATION WITH A SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND AND AN IMMUNOTHERAPEUTIC |
| KR102721494B1 (ko) * | 2018-04-17 | 2024-10-24 | 국립암센터 | 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도 |
| AU2019351273A1 (en) * | 2018-09-27 | 2021-05-20 | Genocea Biosciences, Inc. | Treatment methods |
| KR102300846B1 (ko) * | 2019-11-01 | 2021-09-09 | 서울대학교산학협력단 | 면역 활성 개선용 조성물 및 이의 방법 |
| EP4061409A4 (en) * | 2019-11-18 | 2023-12-27 | Children's Medical Center Corporation | Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy |
| EP4097142A4 (en) * | 2020-01-30 | 2024-05-22 | Apeximmune Therapeutics Inc. | METHODS AND COMPOSITIONS FOR TREATING CANCER OR VIRAL INFECTION WITH A PLA2G2D ANTAGONIST |
| CN113045661B (zh) | 2021-04-07 | 2022-06-21 | 中美冠科生物技术（太仓）有限公司 | 新型抗cd4抗体 |
| CN121001742A (zh) * | 2023-02-06 | 2025-11-21 | Gmp生物技术有限公司 | 用于癌症的mtor治疗剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| GB2302353B (en) | 1995-06-21 | 1998-11-11 | British Gas Plc | Method of filling an excavated opening |
| GB0217777D0 (en) | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
| US7438907B2 (en) | 2002-11-15 | 2008-10-21 | Genmab A/S | Human monoclonal antibodies against CD25 |
| AU2005302459A1 (en) | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| US20090317407A1 (en) * | 2006-05-02 | 2009-12-24 | Lacelle Michael G | Augmentation of immune response to cancer vaccine |
| WO2007143212A1 (en) | 2006-06-02 | 2007-12-13 | Ariad Gene Therapeutics, Inc. | Capecitabine combination therapy |
| CA2652924A1 (en) | 2006-06-19 | 2007-12-27 | Wyeth | Methods of modulating il-22 and il-17 |
| US20080112888A1 (en) | 2006-06-30 | 2008-05-15 | Schering Corporation | Igfbp2 biomarker |
| CN102203132A (zh) * | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2010074266A1 (ja) * | 2008-12-26 | 2010-07-01 | 協和発酵キリン株式会社 | 抗cd4抗体 |
| CN102281761A (zh) | 2009-01-14 | 2011-12-14 | 健康研究股份有限公司 | 用于增强免疫应答的方法和含有mTOR抑制剂的组合物 |
| WO2010124498A1 (en) | 2009-04-30 | 2010-11-04 | Beijing Cellonis Biotechnology Co., Ltd | A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine |
| CA3083324A1 (en) * | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| WO2011133636A1 (en) | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
| WO2011139738A2 (en) * | 2010-04-28 | 2011-11-10 | Tenx Biopharma, Inc. | Therapies using zanolimumab to enhance the immune response |
| US9308253B2 (en) | 2011-09-19 | 2016-04-12 | The Johns Hopkins University | Cancer immunotherapy |
| CA2937035A1 (en) | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| AU2015264528A1 (en) * | 2014-05-21 | 2016-11-03 | Kyowa Hakko Kirin Co., Ltd. | Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer |
| EP3229025B1 (en) | 2014-12-02 | 2019-07-17 | The University of Tokyo | Method for assessing therapeutic effect of anti-cancer agent having anti-cd4 antibody as active ingredient |
-
2015
- 2015-02-05 CA CA2937035A patent/CA2937035A1/en active Pending
- 2015-02-05 EP EP15747022.0A patent/EP3102233B1/en active Active
- 2015-02-05 JP JP2016550261A patent/JP2017507931A/ja active Pending
- 2015-02-05 WO PCT/US2015/014687 patent/WO2015120198A1/en not_active Ceased
- 2015-02-05 US US15/116,485 patent/US11213583B2/en active Active
- 2015-02-05 CN CN201580007415.4A patent/CN105979961B/zh active Active
-
2020
- 2020-08-28 JP JP2020144077A patent/JP7328187B2/ja active Active
-
2021
- 2021-11-22 US US17/533,065 patent/US20220152198A1/en active Pending
-
2023
- 2023-08-03 JP JP2023126665A patent/JP7767361B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023133525A5 (https=) | ||
| JP2017507931A5 (https=) | ||
| JP2017537090A5 (https=) | ||
| JP2024156992A (ja) | 関節リウマチの治療 | |
| TWI877099B (zh) | 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途 | |
| JP2019503387A5 (https=) | ||
| JP2017522307A5 (https=) | ||
| JP2017537105A5 (https=) | ||
| JP2018512397A (ja) | 癌治療の有効性を高めるための組成物及び方法 | |
| JP2021167324A5 (https=) | ||
| JP2021523233A5 (https=) | ||
| JP2021523158A5 (https=) | ||
| JP2019519584A5 (https=) | ||
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| EP4536277A2 (en) | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer | |
| US11684656B2 (en) | Combination therapy for malignant diseases | |
| WO2020243603A1 (en) | Dosing of bispecific t cell engager | |
| JPWO2019246356A5 (https=) | ||
| CN114729054A (zh) | 使用免疫检查点抑制剂抗体治疗癌症的方法和组合 | |
| WO2021178807A1 (en) | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc | |
| JPWO2020160020A5 (https=) | ||
| CN121548431A (zh) | 包含偶联物的药物组合的治疗方法和用途 | |
| Stakiw et al. | A Phase II, Open-label study of an accelerated infusion rate of daratumumab in patients with relapsed and refractory multiple myeloma | |
| US20200148758A1 (en) | Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof | |
| CN113573707A (zh) | 用于治疗癌症的组合产品 |